Nintedanib benefits patients with autoimmune disease-related lung diseases

Written By : Hina Zahid

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2022-03-12 03:30 GMT | Update On 2022-03-12 10:05 GMT

A new clinical published in Arthritis & Rheumatology reveals that nintedanib, a medication that helps prevent changes to lung tissue, may help patients with fibrosing autoimmune disease-related interstitial lung diseases (ILDs), which are a common manifestation of systemic autoimmune diseases such as rheumatoid arthritis.

In the trial, 170 patients with autoimmune disease-related ILDs were randomized to nintedanib or placebo. Investigators assessed patients' forced vital capacity (FVC), or the maximum amount of air one can forcibly exhale from the lungs after fully inhaling. (FVC is a predictor of mortality in patients with autoimmune disease-associated ILDs.)

The rate of decline in FVC over one year was -75.9 mL/year with nintedanib versus -178.6 mL/year with placebo.

"Until now, therapies that can significantly reduce the rate of decline in lung function in connective tissue disease–related ILDs characterized by progressive fibrosis have been lacking. We now have a therapeutic approach that offers a strategy for reducing the morbidity associated with these diseases," said lead author Eric L. Matteson, MD, MPH, of the Mayo Clinic College of Medicine and Science.

https://onlinelibrary.wiley.com/doi/10.1002/art.42075

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Hina Zahid

Hina Zahid Joined Medical Dialogue in 2017 with a passion to work as a Reporter. She coordinates with various national and international journals and association and covers all the stories related to Medical guidelines, Medical Journals, rare medical surgeries as well as all the updates in the medical field. Email: editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Nintedanib benefits patients with autoimmune disease-related lung diseases

Similar News

USFDA grants priority review for Winrevair label update based on ZENITH Trial: Merck

Adult Asthma Linked to Higher Risk of Multiple Comorbidities Over 15 Years: Study

Moderate Increase in Dementia Risk Linked to Tiotropium Use in Older COPD Patients: JAMA

NLR Shows Promise in Asthma Detection and Severity Stratification: Meta-Analysis

Night Shifts Linked to Increased Asthma Risk in Postmenopausal Women: Study

Medical Bulletin 01/Jul/2025

1 in 5 TB Survivors Develop COPD Within 11 Years, Shows Long-Term Korean Study

Digital inhalers may detect early warning signs of COPD flare-ups: Study